Lu Zuohua, Ni Weifeng, Wu Yuding, Zhai Bin, Zhao Qiuyun, Zheng Tian, Liu Qianqian, Ding Dapeng
Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, China.
Department of Endocrinology, Rheumatology and Immunology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Front Med (Lausanne). 2025 Apr 30;12:1560222. doi: 10.3389/fmed.2025.1560222. eCollection 2025.
Worldwide, kidney disease has grown to be an important global public health agenda that reduces longevity. Medical institutions around the globe should enhance screening efforts for kidney disease, to facilitate early kidney disease detection, diagnosis, and intervention. Common screening methods for nephropathy encompass renal tissue biopsy, urine dry chemistry tests, urine formed element analysis, and urine-specific protein assays, among others. These methodologies evaluate renal health by scrutinizing a spectrum of biomarkers. Precise classification and quantitative analysis of these biomarkers can assist in determining the site and extent of kidney injury, as well as in assessing treatment efficacy and prognosis. In this paper, we reviewed the methods and biomarkers for kidney disease and also the integration of multiple biomarkers. With the aim of reasonable applying these markers to the early detection, accurate diagnosis, and scientific management of kidney disease, thereby mitigating the threat posed by kidney disease to human health.
在全球范围内,肾脏疾病已成为一项重要的全球公共卫生议程,它缩短了人类寿命。全球各地的医疗机构应加强对肾脏疾病的筛查工作,以便于早期发现、诊断和干预肾脏疾病。肾病的常见筛查方法包括肾组织活检、尿液干化学检测、尿有形成分分析和尿特异性蛋白检测等。这些方法通过检查一系列生物标志物来评估肾脏健康状况。对这些生物标志物进行精确分类和定量分析有助于确定肾脏损伤的部位和程度,以及评估治疗效果和预后。在本文中,我们回顾了肾脏疾病的检测方法、生物标志物以及多种生物标志物的整合情况。目的是合理应用这些标志物进行肾脏疾病的早期检测、准确诊断和科学管理,从而减轻肾脏疾病对人类健康构成的威胁。